MDGL — Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc. (MDGL) 是一家生物科技公司，屬於醫療保健產業, 目前交易價格為 $524.99. 其SharesGrow評分為 54/100, 表明一般的投資特徵， 7項中通過2項.

分析師共識目標價為 MDGL = $706 (+34.4% 上漲空間).

估值: MDGL 本益比(P/E)為 -40.3 (S&P 500平均約25) 前瞻PEG為 0.11.

財務數據: 營收為 $958M, +432.1%/yr 平均成長. 淨利潤為 $288M (虧損), 成長率為 -4.4%/yr. 淨利潤率為 -30.1% (負值). 毛利率為 94.1% (-2.4 pp 趨勢).

資產負債表: 總債務為 $354M 對比 $603M 股東權益 (D/E比率 0.59, 適度). 流動比率為 4.01 (流動性強). 資產負債率為 28.1%. 總資產: $1.3B.

分析師展望: 20 / 23 位分析師評級 MDGL 為買入 (87%) — 強烈共識.

SharesGrow 7項標準細分: Value 96/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 50/100 (Partial), Moat 67/100 (Partial), Future 94/100 (Pass), Income 10/100 (Fail).

$705.67

▲ 34.42% 上漲空間

Average Price Target

基於 23 位華爾街分析師對 Madrigal Pharmaceuticals, Inc. 提供的12個月價格目標，平均目標價為 $705.67，最高預測為 $964.00，最低預測為 $527.00。

Highest Price Target

$964.00

Average Price Target

$705.67

Lowest Price Target

$527.00

MDGL SharesGrow 評分概覽

63/100

SharesGrow Score

Above average fundamentals

View full scorecard →

價值 96/100

估值 — P/E, PEG, Forward PEG

成長 58/100

財務數據 — 平均成長

過去 0/100

強勁 — 趨勢

健康 50/100

資產負債表 — D/E比率, 流動比率為

護城河 67/100

毛利率為 + market cap

未來 94/100

分析師展望 — 為買入

收入 10/100

淨利潤率為

Scores derived from financial statements, analyst ratings, and balance sheet data.

評分明細 — MDGL

✓

價值 Pass

96/100

MDGL 本益比(P/E)為 -40.3 (S&P 500平均約25). Forward PEG 0.11 — Peter Lynch 被低估 (≤1.0). 分析師共識目標價為 $706, 意味著 +34.5% 相對於當前價格 $525. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + 上漲空間 (25%) + trailing PEG (20%). ≥ 60 = Pass.

MDGL: +432.1%/yr 營收為, -4.4%/yr 淨利潤為平均成長. 一般. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

No analyst coverage available for this stock.

~

健康 Partial

50/100

資產負債表 MDGL: D/E比率 0.59 (適度), 流動比率為 4.01 (流動性強). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

MDGL: 毛利率為 94.1% (-2.4 pp 趨勢), $12B market cap. Moat (0-100): margin (35%) + 趨勢 (15%) + market cap (30%) + 營收為 (20%). Score 67/100. ≥ 70 = Pass.

分析師展望: 20 / 23 位分析師評級 MDGL 為買入 (87%). 分析師共識目標價為 $706 (+34.5% 上漲空間). Score: 60% buy consensus + 40% 上漲空間. ≥ 60 = Pass.

MDGL: 淨利潤率為 -30.1%. 負值. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

市場數據

52週區間265-615

成交量296.4K

30日平均成交量365.71K

市值$12.04B

Beta（1年）-1.01

Share Statistics

EPS（TTM）-12.85

流通股數$22.43M

IPO Date2007-02-06

Employees528

CEOWilliam J. Sibold

Financial Highlights & Ratios

Revenue (TTM)$958.4M

Gross Profit$902.26M

EBITDA$-264.47M

Net Income$-288.28M

Operating Income$-300.1M

Total Cash$983.56M

Total Debt$354.36M

Net Debt$155.67M

Total Assets$1.26B

Price / Earnings (P/E)-40.9

Price / Sales (P/S)12.57

Analyst Forecast

1Y Price Target$640.00

Target High$964.00

Target Low$527.00

上漲空間+21.9%

評級共識Buy

覆蓋分析師數23

買入 87% 持有 9% 賣出 4%

Price Target Summary

公司資訊

國家US

交易所NASDAQ Global Select

貨幣USD

ISINUS5588681057

股價走勢

MDGL

Madrigal Pharmaceuticals, Inc. ↗ · NASDAQ Global Select

Healthcare • Biotechnology

265.00 52WK RANGE 615.00

其他人也在看

KRYS

Krystal Biotech, Inc.

PTC Therapeutics, Inc.

$73.01

+3.68%

TGTX

TG Therapeutics, Inc.

$34.56

+2.28%

TERN

Terns Pharmaceuticals, Inc.

$52.68

+0.13%

VKTX

Viking Therapeutics, Inc.

$35.52

+1.46%

SRPT

Sarepta Therapeutics, Inc.

$22.15

+1.65%

DAWN

Day One Biopharmaceuticals, Inc.

$21.46

-0.14%

Madrigal Pharmaceuticals, Inc. MDGL NASDAQ

MDGL SharesGrow 評分概覽

評分明細 — MDGL

Stock Chart & Stats

股價走勢

其他人也在看

獲取低估股票提醒